Pseudobulbar Affect
📧 Sign up to get email alerts when something new happens for Pseudobulbar Affect.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2025-01-29Clinical Trial Update: Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect [NA]
Clinical trial investigating structural and functional brain networks in amyotrophic lateral sclerosis and pseudobulbar affect. The study is…
-
FDA approval · 2024-08-28FDA Approved: DEXTROMETHORPHAN HYDROBROMIDE AND QUINIDINE SULFATE — Original Application (Camber Pharmaceuticals, Inc.)
The FDA approved Camber Pharmaceuticals' original application for a generic combination product of dextromethorphan hydrobromide and quinidi…
-
CLINICAL_TRIALS research · 2024-06-13Clinical Trial Update: Piloting the Attention Training Technique for Post-Stroke Emotionalism [NA]
A pilot study from University of Manchester evaluating Attention Training Technique for post-stroke emotionalism, currently not yet recruiti…
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease [Phase 4]
Phase 4 clinical trial update for Nuedexta in treating pseudobulbar affect in patients with Alzheimer's disease; study status terminated.
-
FDA approval · 2019-06-11FDA Approved: NUEDEXTA — Supplemental Application (Otsuka America Pharmaceutical, Inc)
FDA approved a supplemental application for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) from Otsuka America Pharmaceutica…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2019-01-31FDA Approved: NUEDEXTA — Supplemental Application (Otsuka America Pharmaceutical, Inc)
FDA approved a supplemental application for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) from Otsuka America Pharmaceutica…
-
CLINICAL_TRIALS trial_result · 2017-07-03Clinical Trial Update: Effectiveness, Safety, and Health-Related Outcomes of NUEDEXTA® in Nursing Home Patients With Pseudobulbar Affect (PBA) [Phase 4]
Phase 4 trial evaluating effectiveness, safety, and health-related outcomes of NUEDEXTA in nursing home patients with pseudobulbar affect wa…
-
FDA approval · 2017-04-21FDA Approved: NUEDEXTA — Supplemental Application (Otsuka America Pharmaceutical, Inc)
FDA approved a supplemental application for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) from Otsuka America Pharmaceutica…
-
CLINICAL_TRIALS trial_result · 2017-03-15Clinical Trial Update: Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA) [Phase 4]
Phase 4 trial evaluating the safety, tolerability and effectiveness of Nuedexta in treating Pseudobulbar Affect; results from the study have…
-
CLINICAL_TRIALS trial_result · 2016-07-14Clinical Trial Update: Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients [Phase 3]
This clinical trial update covers safety and efficacy data from a Phase 3 study of AVP-923 for pseudobulbar affect in patients with multiple…
-
FDA approval · 2015-08-14FDA Approved: NUEDEXTA — Supplemental Application (Otsuka America Pharmaceutical, Inc)
FDA approved a supplemental application for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) submitted by Otsuka America Pharm…
-
FDA approval · 2015-01-20FDA Approved: NUEDEXTA — Supplemental Application (Otsuka America Pharmaceutical, Inc)
The FDA approved a supplemental application for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) filed by Otsuka America Pharm…
-
CLINICAL_TRIALS trial_result · 2013-07-10Clinical Trial Update: Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS [Phase 3]
Phase 3 trial assessing safety and efficacy of AVP-923 for pseudobulbar affect in patients with ALS or MS; results were posted in 2013.
-
EMA approval · 2013-04-26European Medicines Agency recommends approval of first treatment for pseudobulbar affect
The EMA recommends approval of the first treatment specifically targeting pseudobulbar affect, signaling a new therapeutic option for this c…
-
FDA approval · 2012-11-30FDA Approved: NUEDEXTA — Supplemental Application (Otsuka America Pharmaceutical, Inc)
The FDA approved a supplemental application for NUEDEXTA (dextromethorphan hydrobromide and quinidine sulfate) submitted by Otsuka America P…
-
FDA approval · 2010-10-29FDA Approved: NUEDEXTA — Original Application (Otsuka America Pharmaceutical, Inc)
FDA approved NUEDEXTA from the Original Application (NDA) for the fixed-dose combination of dextromethorphan hydrobromide and quinidine sulf…